单克隆抗体治疗 (mAB) 市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00003417
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Buy Now

【研究报告】单克隆抗体治疗(mAB)市场规模预计将从2022年的1920.4亿美元增长到2030年的5428.0亿美元;预计 2022 年至 2030 年市场复合年增长率为 13.9%。
市场洞察和分析师观点:
稳健的研发和慢性病患病率的增加可能会对单克隆抗体产生重大影响未来几年抗体治疗 (mAB) 市场预测
单克隆抗体 (mAb) 药物是对选定目标抗原具有特异性的抗体的同质集合。治疗性单克隆抗体的生产过程需要哺乳动物表达系统提供糖基化、折叠、定向和共价结合抗体肽链所必需的细胞机制,以产生完整的具有生物功能的分子。双特异性和三特异性抗体等新型抗体可识别单个抗原上的多个表位,而单域抗体可以更轻松地穿透组织。这种先进的抗体类型可以提高抗体疗法的效率,从而扩大其应用领域。这些抗体还可以形成抗体-药物偶联物,以提高化疗药物针对特定细胞类型的效率。用于治疗多种疾病的基于 mAB 的药物的生产推动了市场的发展。制造商通过战略发展推出的创新产品是利润丰厚的市场机会。此外,含有 mAB 的组合药物成为 mAb 治疗市场的市场趋势。
市场驱动力
生产基于 mAB 的药物来治疗多种疾病推动市场增长
单克隆抗体疗法 (mAB) 用于治疗多种疾病,包括癌症、自身免疫性疾病和代谢性疾病。生物制药公司和科研院所生产的此类药物因其特异性高、靶向能力强、毒副作用低而受到全球市场的广泛关注。因此,单克隆抗体治疗药物生产能力的提高预计将推动单克隆抗体治疗药物 (mAB) 市场的增长
欧盟 (EU) 和美国批准的治疗性单克隆抗体
产品
品牌名称
疾病适应症
批准年份:欧盟
批准年份:美国
Pozelimab
VEOPOZ
CHAPLE 疾病
NA
2023
Elranatamab
Elrexfio
多发性骨髓瘤
2023
2023
Rozanolixizumab
RYSTIGGO
全身性重症肌无力
2024
2023
他克他单抗
TALVEY
多发性骨髓瘤
2023
2023
Epcoritamab
EPKINLY
弥漫性大 B 细胞淋巴瘤
2023
2023
Mirikizumab
Omvoh
溃疡性结肠炎
2023
2023
资料来源:抗体协会
市场机会
制造商通过战略发展推出创新产品
治疗性单克隆抗体制造商推出的产品等有机开发可能会在未来提振单克隆抗体治疗 (mAB) 市场年。 2022年3月,Adagio Therapeutics, Inc.宣布推出ADG20(ADINTREVIMAB)。新推出的产品是第一个通过寻求美国紧急使用授权 (EUA) 达到主要终点的单克隆抗体,在 COVID-19 暴露前和暴露后预防和治疗方面具有统计显着性。
此外,合并等无机发展收购将导致新的治疗性单克隆抗体的推出。例如,2023年7月,礼来公司宣布收购Versanis,这是一家旨在治疗心脏代谢疾病的私人临床阶段生物制药公司。礼来公司收购 Versanis 以获得其核心产品组合,包括名为 bimagrumab 的单克隆抗体产品。该产品目前正在“BELIEVE 2b 期研究”中作为独立分子进行评估。它还与索马鲁肽结合进行研究,以了解其在减少脂肪量、保持肌肉质量以及为肥胖症和肥胖相关并发症患者提供更好的患者治疗效果方面的综合潜力。上述因素是影响未来几年单克隆抗体治疗 (mAB) 市场增长的因素。
单克隆抗体治疗 (mAB) 市场趋势
含有单克隆抗体 (mAB) 的组合药物
根据国家研究所的数据根据美国卫生研究院 (NIH) 2021 年报告,罗氏和再生元(制药公司)启动了 2/3 期临床试验,以评估组合单克隆抗体对轻度至中度 COVID-19 患者的疗效。他们正在研究“REGN-COV2”,这是一种由两种单克隆抗体(casirivimab 和 imdevimab)组合而成的鸡尾酒药物,用于治疗 COVID-19。这些公司预计,这种mAB药物的组合可以减少70%的住院治疗,并且对12岁以上的儿童(体重超过40公斤)更有效。研究人员正在大力寻找更多这样的单克隆抗体治疗组合。例如,礼来公司开发的bamlanivimab和etesivimab在2022年针对COVID-19显示出积极的临床结果。因此,治疗多种疾病的单克隆抗体组合药物将在未来几年受到广泛关注,从而成为未来几年的一个突出趋势。单克隆抗体治疗 (mAB) 市场。
战略见解
报告细分和范围:
单克隆抗体治疗 (mAB) 市场分析已通过考虑以下细分进行:产品、应用和分销渠道
根据产品,市场分为重组单克隆抗体、抗体药物偶联物、双特异性和多特异性单克隆抗体、生物仿制药等。单克隆抗体治疗(mAB)市场按应用分为肿瘤学、自身免疫性疾病等。自身免疫性疾病市场进一步细分为类风湿性关节炎、牛皮癣、溃疡性结肠炎等。单克隆抗体治疗 (mAB) 市场根据分销渠道分为医院药房、零售药房等。
就产品而言,重组单克隆抗体治疗 (mAB) 细分市场占有最大的单克隆抗体治疗 (mAB) 市场份额2022 年。预计抗体-药物偶联物领域在预测期内将创下 18.5% 的最快复合年增长率。根据 ACS Publications 的报告,治疗性重组单克隆抗体反映了最先进的生物医学研究,通过规划有效策略来治疗多种尚无有效治疗方法的疾病。托珠单抗是用于治疗关节炎、特发性关节炎和类风湿性关节炎 (RA) 的重组 mAB 药物的一个例子。此外,重组单克隆抗体还可用于治疗自身免疫性疾病和癌症等疾病。贝伐珠单抗是目前用于治疗乳腺癌、肺癌和结直肠癌的重组单克隆抗体的一个例子; HIV-1;细菌毒素感染/反应,以及 SARS-CoV-2 和埃博拉病毒感染。
抗体药物偶联物 (ADC) 是一类快速新兴的治疗剂,也是一类利用化疗组合的新型高效药物和免疫疗法。根据NIH的报告,目前ADC主要基于免疫球蛋白G(IgG),截至目前,美国食品药品监督管理局(FDA)已批准了13种ADC。此外,超过 90 种 ADC 正在进行临床开发/试验。
Sr.编号
产品(批准的 ADC)
疾病适应症
1
Mylotarg
复发性急性髓性白血病
2
Adcetris
复发性霍奇金淋巴瘤和复发性系统性间变性大细胞淋巴瘤
3
Kadcyla
HER2 阳性转移性乳腺癌
4
Besponsa
复发或难治性 CD22 阳性 B 细胞前体急性淋巴细胞白血病
5
Lumoxiti
复发或难治性毛细胞白血病或 HCL
6
Polivy
复发或难治性 (R/R) 弥漫性大 B 细胞淋巴瘤或 DLBCL
7
Padcev
转移性尿路上皮癌
8
Enhertu
转移性 HER2 阳性乳腺癌
9
Trodelvy
转移性三阴性乳腺癌
10
Blenrep
复发或难治性多发性骨髓瘤
11
Zynlota
大 B 细胞淋巴瘤
12
Tivdak
复发或转移性宫颈癌治疗
13
Elahere
铂耐药卵巢癌症
来源:一次性支持文章
因此,ADC 的监管批准和正在进行的罕见疾病治疗方法临床试验促进了抗体药物偶联物领域单克隆抗体治疗 (mAB) 市场的增长预测期。
单克隆抗体治疗 (mAB) 市场,按应用划分 – 2022 年和 2030 年
区域分析:
根据地理位置,单克隆抗体治疗 (mAB) 市场报告涵盖北美、欧洲、亚太地区、中东和非洲以及南美洲和中美洲。 2022年,北美占据全球最大的单克隆抗体治疗(mAB)市场份额。亚太地区预计 2022 年至 2030 年复合年增长率最高。在北美,美国占据最大的市场份额。 mAB 疗法的加速产品审批程序有利于该国的市场。根据 BioMed Central 杂志发表的一项研究显示的统计数据,截至 2019 年 12 月,美国 FDA 批准了 79 种治疗性 mAB。在 79 种治疗性 mAB 中,有 30 种用于癌症治疗。 2021 年 5 月,FDA 宣布授权 EUA 使用新型治疗性单克隆抗体 Sotrovimab,该药物旨在用于门诊治疗患有严重 COVID-19 病症的患者。 2022 年 2 月,FDA 宣布为 Elli Lilly and Company 生产的 bebtelovimab 发放 EUA,这是针对 Omicron 变种的 mAB 的一个例子。此外,etesevimab 也是美国 FDA 批准的治疗性 mAB 的一个例子。
单克隆抗体治疗 (mAB) 行业发展和未来机遇:
单克隆抗体治疗 (mAB) 市场领先企业的各种战略发展如下所列:
2023 年 1 月,阿斯利康 Evusheld 在欧盟 (EU) 获得批准。 Evusheld 是两种长效抗体的组合:tixagevimab (AZD8895) 和 cilgavimab (AZD1061)。美国政府通过卫生与公众服务部、战略准备与响应管理局以及生物医学高级研究与开发局的联邦资金对该产品的开发提供支持。2023 年 8 月,再生元制药公司 (Regeneron Pharmaceuticals, Inc.) 进入与生物医学高级研究与开发局 (BARDA) 达成协议,支持针对 COVID-19 的下一代单克隆抗体疗法的临床开发、临床制造和监管许可流程。根据该协议,Regeneron 计划与 BARDA 合作评估并进一步开发和生产该疗法,并开展监管活动。竞争格局和主要公司:
葛兰素史克 (GlaxoSmithKline)、F.Hoffmann-La-Roche、拜耳 AG (Bayer AG)、安进 (Amgen)、诺华、艾伯维、百时美施贵宝、杨森制药、默克和阿斯利康都是单克隆抗体治疗 (mAB) 市场的知名公司。单克隆抗体治疗 (mAB) 市场报告包括公司定位和专注度,以评估市场主要参与者的表现。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which application segment held the largest share in the monoclonal antibody therapeutics market?

The autoimmune disease segment dominated the global monoclonal antibody therapeutics market and held the largest market share in 2022.

Who are the key players in the monoclonal antibody therapeutics market?

The monoclonal antibody therapeutics market majorly consists of the players such GlaxoSmithKline, F.Hoffmann-La-Roche, Bayer AG, Amgen, Novartis, AbbVie, Bristol-Myers Squibb, Janssen Pharmaceutical, Merck KgaA, and AstraZeneca, and amongst others.

Which region is expected to witness significant demand for monoclonal antibody therapeutics market in the coming years?

Global monoclonal antibody therapeutics market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. North America held the largest market share of the monoclonal antibody therapeutics market in 2022.

Which product segment leads the monoclonal antibody therapeutics market?

The recombinant mABs segment held the largest share of the market in the global monoclonal antibody therapeutics market and held the largest market share in 2022.

Which are the top companies that hold the market share in monoclonal antibody therapeutics market?

Amgen and GlaxoSmithKline are the top two companies that hold huge market shares in the monoclonal antibody therapeutics market.

What is monoclonal antibody therapeutics market?

Monoclonal antibody (mAbs) therapeutics is a homogenous collection of antibodies used to treat illness and are selected to target antigens. Therapeutic mAbs require a mammalian expression system offering the cell machinery required to glycosylate, fold, orient, and covalently bind antibody peptide chains to produce complete and biologically functional molecules. Also, the therapeutic antibody is expanding the use of new modality antibodies such as bispecific and trispecific antibodies to recognize the multiple epitopes on the same antigen and single domain antibodies that can more easily penetrate tissues and antibody-drug conjugates for targeting chemotherapy agents to specific cell types.

What is the market CAGR value of monoclonal antibody therapeutics market during forecast period?

The CAGR value of the monoclonal antibody therapeutics market during the forecasted period of 2022-2030 is 13.9%.

What are the driving factors for the monoclonal antibody therapeutics market across the globe?

Key factors that are driving the growth of this market are production of mabs-based drugs to treat several infectious diseases is expected to boost the market growth for the monoclonal antibody therapeutics over the years.

The List of Companies - Monoclonal Antibody Therapeutics (mABs) Market

  1. GlaxoSmithKline
  2. F.Hoffmann-La-Roche
  3. Bayer AG
  4. Amgen
  5. Novartis
  6. AbbVie
  7. Bristol-Myers Squibb
  8. Janssen Pharmaceutical
  9. Merck KgaA
  10. AstraZeneca

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports